Biotech startup Scala Biodesign has secured $16 million in new funding to expand its AI-driven protein development platform, ScalaOS. The investment round, led by Grove Ventures, brings the company’s total funding to over $21 million since its founding in 2022. The capital will be used to scale operations globally, enhance its computational systems, and grow both its scientific and engineering teams as demand for advanced biotechnology solutions increases.

ScalaOS is designed to accelerate protein engineering, a critical process in the development of medicines, vaccines, and industrial applications. Traditional methods often require years of trial-and-error experimentation, but Scala’s platform integrates artificial intelligence with physics-based modeling and evolutionary data to optimize proteins more efficiently. By streamlining this process, the company aims to reduce development timelines and improve the performance and stability of engineered proteins.

The platform is already gaining traction, with adoption reported among several of the world’s largest pharmaceutical companies. By enabling faster and more precise protein design, Scala Biodesign is positioning itself at the forefront of AI-driven biotechnology innovation. As the intersection of artificial intelligence and life sciences continues to expand, tools like ScalaOS could play a significant role in shaping the future of drug development and industrial biotechnologies.

SOURCE: Ynet